The FDA has issued a new boxed warning for Droxia (hydroxyurea). Also, according to a new study, RA patients receiving rituximab should be monitored for late-onset neutropenia…
Search results for: rituximab
Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
Study: Inflammation Starts Earlier Than You Think
A recently published study shows that inflammatory disease begins well before synovitis is seen on exam; a better understanding of what’s brewing before the storm could lead to the development of preventive therapies for RA.
The Promise of Hope in Lupus Nephritis
Explore the latest lupus nephritis advances in this supplement, covering CAR-T therapy, obinutuzumab data & new diagnostic tools.
Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus
This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Reflections on B Cells in SLE & Lupus Nephritis
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
2024 ACR Guideline for the Screening, Treatment & Management of Lupus Nephritis
Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.
Obinutuzumab Aids Standard Therapy for Lupus Nephritis
Phase 3 REGENCY data: Obinutuzumab & standard therapy improve complete renal response rates in active lupus nephritis patients.
B Cell-Depleting Therapy in SLE & Lupus Nephritis
“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 47
- Next Page »